FASN and cancer: While the IHC-quantified ATF6 expression did not associate with CRC human disease-free survival in our human cohorts (Extended Data Fig. 3b–d), Kaplan–Meier analysis in both databases showed a significantly reduced disease-free survival in cases that were classed as ATF6-only amp/gain (P < 0.001 pan-cancer, P = 0.0122 TCGA) and those classed as combined ATF6 and FASN amp/gain (P < 0.0001 pan-cancer, P < 0.0001 TCGA), compared to those cases unaltered in either of the two genes (Extended Data Fig. 3e,f).